Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

ABO Identical and Washed Transfusions Are Candidate Strategies to Reduce Early Mortality in Acute Promyelocytic Leukemia (APL)

Majed A. Refaai, MD, Kelly F Henrichs, BS, MT(ASCP), Joanna M. Heal, MBBS, MRCP, Amy E Schmidt, MD PhD, Jason H. Mendler, MD PhD, Scott A. Kirkley, MD, Christopher Aquina, MD, Debra Masel, BS, MT(ASCP) SBB, Jane Liesveld, MD, Neil Blumberg, MD

Blood (2016) 128 (22): 4011.

https://doi.org/10.1182/blood.V128.22.4011.4011

Published: 2016

Journal Articles

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

Amin M. Alousi, Jennifer Le-Rademacher, Rima M. Saliba, Frederick R. Appelbaum, Andrew Artz, Jonathan Benjamin, Steven M. Devine, Fangyu Kan, Mary J. Laughlin, Hillard M. Lazarus, Jane Liesveld, Miguel-Angel Perales, Richard T. Maziarz, Mitchell Sabloff, Edmund K. Waller, Mary Eapen, Richard E. Champlin

Blood (2013) 121 (13): 2567–2573.

https://doi.org/10.1182/blood-2012-08-453860

Published: 2013

Journal Articles

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Mikkael A. Sekeres, Holly Gundacker, Jeffrey Lancet, Anjali Advani, Stephen Petersdorf, Jane Liesveld, Deborah Mulford, Tom Norwood, Cheryl L. Willman, Frederick R. Appelbaum, Alan F. List

Blood (2011) 118 (3): 523–528.

https://doi.org/10.1182/blood-2011-02-337303

Published: 2011

Journal Articles

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick Peterson, Lynn Rich, Susan Blumel, Nicole K. Proia, Jane Liesveld, Richard I. Fisher, James O. Armitage, Steven Grant, John P. Leonard

Blood (2011) 117 (10): 2807–2812.

https://doi.org/10.1182/blood-2010-11-314708

Published: 2011

Journal Articles

Activity and Cytotoxicity of Algae Extracts On Normal and Leukemic Hematopoietic Cells.

Jeremy Bechelli, M.S., Karen Rosell, BS, Myra Coppage, PhD, Jane Liesveld, MD

Blood (2009) 114 (22): 4815.

https://doi.org/10.1182/blood.V114.22.4815.4815

Published: 2009

Journal Articles

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Jennifer L Kelly, PhDMPH, Faith Young, MD, Jane Liesveld, MD, James O. Armitage, M.D., Nicole Proia, MPH, Kim Cruttenden, N.P., John P. Leonard, MD

Blood (2009) 114 (22): 924.

https://doi.org/10.1182/blood.V114.22.924.924

Published: 2009

Journal Articles

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Blood (2008) 112 (11): 573.

https://doi.org/10.1182/blood.V112.11.573.573

Published: 2008

Journal Articles

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Dianna Howard, MD, Jane Liesveld, MD, Gordon L. Phillips, II, MD, Monica L. Guzman, PhD, Craig T. Jordan, PhD

Blood (2008) 112 (11): 2953.

https://doi.org/10.1182/blood.V112.11.2953.2953

Published: 2008

Journal Articles

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Willis H. Navarro, MD, Manza-A Agovi, MPH, Brent Logan, PhD, Andrea Bacigalupo, MD, Karen K Ballen, MD, Brian J. Bolwell, MD, Haydar Frangoul, MD, Vikas Gupta, MD, MRCP, MRCPath, Theresa Hahn, PhD, Mark Juckett, MD, Hillard M. Lazarus, MD, Mark R. Litzow, MD, Jane Liesveld, MD, Jan Moreb, MD, David Marks, MD, PhD, Philip L. McCarthy, MD, J. Douglas Rizzo, MD, MS

Blood (2008) 112 (11): 51.

https://doi.org/10.1182/blood.V112.11.51.51

Published: 2008

Journal Articles

Taking a SNPshot of t-AML

Jane Liesveld

Blood (2008) 112 (3): 458–459.

https://doi.org/10.1182/blood-2008-05-156703

Published: 2008

Journal Articles

Long-Term Outcome of Autologous Stem Cell Transplantation (ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic Era.

Jonathan W. Friedberg, Elizabeth Sensenig, Jennifer Kelly, Jamie Oliva, Louis Constine, Michael Becker, Gordon Phillips, Jane Liesveld, Richard I. Fisher, Steven H. Bernstein

Blood (2007) 110 (11): 1907.

https://doi.org/10.1182/blood.V110.11.1907.1907

Published: 2007

Journal Articles

Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL).

Jonathan W. Friedberg, Jennifer Kelly, Susan Voci, Diana Marquis, Lynn Rich, Randall Rossi, Steven Bernstein, Craig Jordan, Jane Liesveld, Richard I. Fisher

Blood (2007) 110 (11): 2325.

https://doi.org/10.1182/blood.V110.11.2325.2325

Published: 2007

Journal Articles

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Jennifer R. Brown, MD, PhD, Jonathan Friedberg, MD, Yang Feng, MS, Kimberly Phillips, BA, Jennifer C. Clark, MA, Paola dal Cin, PhD, Robin Joyce, MD, David C. Fisher, MD, Richard I. Fisher, MD, Ronald W. Takvorian, MD, Jane Liesveld, MD, Diana Marquis, BS, Donna Neuberg, ScD, Arnold S. Freedman, MD

Blood (2007) 110 (11): 1358.

https://doi.org/10.1182/blood.V110.11.1358.1358

Published: 2007

Journal Articles

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Jonathan W. Friedberg, MD, MMSc, Jennifer Kelly, MPH, Jeffrey L. Kutok, MD, Rabih Salloum, MD, David C. Fisher, MD, Elizabeth Ronan, Virginia Dalton, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, MD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD

Blood (2006) 108 (11): 2713.

https://doi.org/10.1182/blood.V108.11.2713.2713

Published: 2006

Journal Articles

Patterns and Timing of Initial Relapse in Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma.

Sughosh Dhakal, BS, Tithi Biswas, M.D., Sheema Chawla, M.D., Nikhil Uppal, M.D., Christopher Beck, Ph.D., Sarada Uppuluri, B.S., Jane Liesveld, M.D., Ann Muhs, B.A, Gordon Phillips, M.D., Louis Constine, M.D.

Blood (2006) 108 (11): 3673.

https://doi.org/10.1182/blood.V108.11.3673.3673

Published: 2006

Journal Articles

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Jonathan W. Friedberg, MD, Jennifer Kelly, Jeffrey L. Kutok, MD, Rabih Salloum, MD, Thomas Brenn, MD, David C. Fisher, MD, Elizabeth Ronan, Mary McCauley, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, PhD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD

Blood (2005) 106 (11): 2434.

https://doi.org/10.1182/blood.V106.11.2434.2434

Published: 2005

Journal Articles

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

Michael J. Dugan, MD, Luke P. Akard, MD, James M. Thompson, DO, Auayporn Nademanee, MD, Richard T. Maziarz, MD, William I. Bensinger, MD, Jane Liesveld, MD, Karin Badel, Christine Dehner, Colleen Gibney, Gary Calandra, Jan Jansen, MD, PhD

Blood (2004) 104 (11): 2860.

https://doi.org/10.1182/blood.V104.11.2860.2860

Published: 2004

Journal Articles

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann, David W. End, John J. Wright, Kees Bol, Ivan Horak, Michael L. Tidwell, Jane Liesveld, Timothy J. Kottke, Dawn Ange, Laxmi Buddharaju, Ivana Gojo, W. Edward Highsmith, Robert T. Belly, Raymond J. Hohl, Mary Ellen Rybak, Alain Thibault, Joseph Rosenblatt

Blood (2001) 97 (11): 3361–3369.

https://doi.org/10.1182/blood.V97.11.3361

Published: 2001

NARROW

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

ABO Identical and Washed Transfusions Are Candidate Strategies to Reduce Early Mortality in Acute Promyelocytic Leukemia (APL)

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Activity and Cytotoxicity of Algae Extracts On Normal and Leukemic Hematopoietic Cells.

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Taking a SNPshot of t-AML

Long-Term Outcome of Autologous Stem Cell Transplantation (ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic Era.

Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL).

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Patterns and Timing of Initial Relapse in Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma.

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only